Global Deutenzalutamide Soft Capsules Market Strategic Research Report

Scope of the Report

The global Deutenzalutamide Soft Capsules market size is predicted to grow from US$ 29.35 million in 2025 to US$ 372 million in 2032; it is expected to grow at a CAGR of 13.3% from 2026 to 2032.

Deutenzalutamide soft capsules are a novel oral androgen receptor inhibitor modified by deuteration. By specifically binding to the androgen receptor and blocking its signal transduction, they inhibit the proliferation and survival of tumor cells, and are mainly used for the treatment of metastatic castration‑resistant prostate cancer. As a deuterated improved drug based on enzalutamide, its structural optimization enhances metabolic stability, prolongs its duration of action in vivo and improves safety. Featuring favorable oral absorption and convenient administration, it provides a better‑tolerated therapeutic option for patients with advanced prostate cancer and holds important clinical value in the field of genitourinary oncology.In 2025, global Deutenzalutamide soft capsules production reached approximately 120,000 units.

Deutenzalutamide soft capsules, as the first deuterated androgen receptor inhibitor approved in China, have filled the gap in domestic innovative drugs for the targeted treatment of metastatic castration‑resistant prostate cancer. Relying on deuteration technology, they have achieved remarkable improvements in metabolic stability and safety, showing clear clinical advantages in reducing central nervous system adverse reactions and enhancing tolerability in elderly patients.

Its market positioning focuses on differentiated therapeutic needs, mainly serving patients intolerant to or with unsatisfactory efficacy from existing medications, thus forming misplaced competition with the original enzalutamide and domestic generics and avoiding fierce price wars.

With the rising incidence of prostate cancer, accelerating population aging, and official inclusion in the medical insurance catalogue in China, the drug’s market accessibility and growth potential have been greatly enhanced, making it an important force for domestic innovative drugs to replace foreign products and seize the high‑end genitourinary oncology market.

In the future, its commercialization will be promoted through the coordination of medical insurance reimbursement, hospital access, and academic promotion. Relying on its unique clinical value and status as a domestic innovative drug, it will continue to expand its share in the rapidly growing prostate cancer drug market.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Deutenzalutamide Soft Capsules market?

What factors are driving Deutenzalutamide Soft Capsules market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Deutenzalutamide Soft Capsules market opportunities vary by end market size?

How does Deutenzalutamide Soft Capsules break out by Type, by Application?

This report presents a comprehensive overview of the global Deutenzalutamide Soft Capsules market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 28 Capsules Per Box
• 112 Capsules Per Bottle

Segment by Combined medication

• Deuteroenzalutamide in combination with Androgen Synthesis Inhibitors
• Deuteroenzalutamide in combination with Hormonal Antineoplastic Drugs

Segment by Production Technology

• Innovator
• Generic

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Metastatic Castration-Resistant Prostate Cancer
• Non-Metastatic Castration-Resistant Prostate Cancer
• Metastatic Hormone-Sensitive Prostate Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Deutenzalutamide Soft Capsules market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Metastatic Castration-Resistant Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact